Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: A randomized, double-blind, controlled study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 563-568

  Lin, Chien Ho ^a   Lin, Shih Hsien ^b   Jang, Fong Lin ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Aripiprazole; major depressive disorder; nonrefractory

Indexed keywords

ARIPIPRAZOLE; PLACEBO; SERTRALINE;

ADJUVANT THERAPY; AGED; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND TREMOR; HEART PALPITATION; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WEAKNESS;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052482886     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822bb0db     Document Type: Article

References (24)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917. (Pubitemid 44807782)
2. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971. (Pubitemid 35388053)
3. Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disorder. 2009;116:4-11.
4. Trivedi MH, Fava M, Marangell LB, et al. Use of treatment algorithms for depression. Prim Care Companion J Clin Psychiatry. 2006;8:291-298.
5. Nakajima S, Suzuki T, Watanabe K, et al. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:259-264.
6. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42:57-90.
7. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980-991.
8. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411. (Pubitemid 41070874)
9. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Arlington, VA: American Psychiatric Association; 2006:592.
10. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136. (Pubitemid 36513927)
11. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843-853. (Pubitemid 47015482)
12. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:156-165. (Pubitemid 351417120)
13. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22:293-299.
14. Basu R, Brar JS. Dose-dependent rapid-onset akathisia with aripiprazole in patients with schizoaffective disorder. Neuropsychiatr Dis Treat. 2006;2:241-243. (Pubitemid 44043619)
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
16. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540-549.
17. Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disorder. 2010;120:133-140.
18. Mahmoud RA, Pandina GJ, Turkoz I. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147:593-602. (Pubitemid 351664478)
19. Terao T. Small doses of aripiprazole augmentation of antidepressant treatment: a report of 3 cases. Prim Care Companion J Clin Psychiatry. 2008;10:252-253. (Pubitemid 351879965)
20. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4:937-948.
21. Chen LC, Schafheutle EI, Noyce PR. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan. Res Soc Adm Pharm. 2009;5:211-224.
22. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003;13:S69-S75. (Pubitemid 37188777)
23. Warden D, Trivedi MH, Wisniewski SR, et al. Identifying risk for attrition during treatment for depression. Psychother Psychosom. 2009;78:372-379.
24. Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22:1825-1837. (Pubitemid 44449239)